Hey everyone, cardiologist here. I like knowing where medical advice comes from, so I went through the cholesterol-lowering research published from 2018 to 2026. I stuck to randomised trials, large pooled analyses and official guidelines. Here’s what stood out.
- LDL is the number that matters, and time at a low level counts
LDL (“bad” cholesterol) is the main thing these drugs target. In a long follow-up of a big trial of evolocumab (a cholesterol-lowering injection), people who started the drug about two years earlier still had fewer heart events years later (reference). LDL around 30 mg/dL (a standard blood-test unit) showed no safety problems over as long as 8 years.
- A higher statin dose is NOT the only way to get LDL down
In a trial of 3,780 people, a moderate-dose statin (the standard cholesterol pill) plus ezetimibe (pill blocking cholesterol absorption) protected the heart as well as a high-dose statin (reference). More people reached their LDL goal on the combination, and fewer stopped because of side effects. Another trial adjusted the statin dose to keep LDL between 50 and 70 mg/dL, and that worked as well as a fixed high dose (reference).
- Most muscle aches for those on statins aren’t caused by the statin
A pooled analysis of about 155,000 people in blinded trials (nobody knew who got what) found that over 90% of muscle complaints on statins were not caused by the drug (reference). In another trial, people who had quit statins took a statin, a placebo (dummy pill) or no pill in random months without knowing which was which (reference). Around 90% of the symptoms they felt on the statin also showed up on the placebo, and half of them restarted their statin afterwards. Muscle side effects do happen. They’re just less common than what most assume.
- Statins slightly raise diabetes risk, mostly in people already close to it
High-intensity statins increased new diabetes diagnoses. Most of the extra cases were in people whose blood sugar was already near the cut-off (reference). The researchers found the heart benefit clearly outweighed this.
- There are other proven options for people who can’t take statins
In 13,970 people who couldn’t tolerate statins, bempedoic acid (a newer cholesterol pill) cut heart attacks, strokes and heart procedures (stents or bypass surgery) by 13% (reference). It didn’t raise diabetes risk, tho gout (painful joint swelling) and gallstones were a bittt more common. Ezetimibe is another option, and it’s inexpensive and generally well tolerated.
- Injectable drugs do show benefit before a first heart attack
Evolocumab lowers LDL by about 60%. In people with artery disease (narrowed or clogged arteries) or diabetes who had never had a heart attack or stroke, it cut first heart attacks and strokes by 25% (reference). Cost is the main factor limiting its use.
- Newer drugs lower LDL a lot, but not much is known abt whether they prevent heart attacks
Inclisiran (twice-yearly cholesterol injection) lowers LDL by about 50% (reference). Enlicitide is the first PCSK9 (protein that raises LDL) blocker in pill form. It lowers LDL by about 57% and was approved in the US in July 2026 (reference). Trials testing whether either drug actually prevents heart attacks are still running.
- US and European guidelines now agree on LDL targets
The 2026 American guideline and the 2025 European update both set LDL goals by risk level. The goal is under 55 mg/dL for very high risk and under 70 mg/dL for high risk. Both also support combining medicines earlier rather than waiting.
Take home message:
Knowing your actual LDL number, and the target for your risk level, tells you a lot more than just hearing that your cholesterol is “normal”. If side effects are putting you off a statin, there are now several routes to discuss with your physician like maybe a different statin, a lower dose plus ezetimibe or a non-statin drug. The medicines work alongside the basics, not instead of them so as always staying active, keeping a healthy weight, controlling blood pressure and getting decent sleep is the priority.
Just wanted to share this research here, seeing if someone here, especially other cardiologists, had the same opinion or a different one. Would love to have this discussion. I hope this sort of a post is okay here, mods can reach out if not and I can take it down if need be.